Nanning

Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.

The trial focuses on hospitalized children aged 0 to 18 years who require gastric tube placement, aiming to improve practices in pediatric enteral nutrition. Researchers are evaluating evidence-based methods to enhance safety and effectiveness in tube placement by addressing gaps between current practices and the latest guidelines. This quality improvement project seeks to update healthcare professionals knowledge and standardize procedures to improve pediatric care quality. The study involves establishing an enteral nutrition management team that will lead a 3-month quality improvement initiative. During this time, pediatric nurses will receive regular training through lectures, group discussions, demonstrations, and simulations focused on gastric tube placement and maintenance. The project will observe changes in compliance with protocols and nursing knowledge as the new practices are implemented. Participants will be monitored through assessments of protocol adherence and knowledge levels before and after the intervention. Data collected will include compliance rates with gastric tube placement protocols and the personal knowledge of nursing staff. The study aims to ensure safer and more effective tube placement, with evaluations conducted throughout the 3-month implementation period and ongoing support for nurses.

Radiation-induced lung injury RILI is a common complication after thoracic radiotherapy, occurring in about 31.4% of patients. This condition, sometimes combined with immune-checkpoint inhibitor-related pneumonitis CIP, can disrupt cancer treatment and negatively affect patient outcomes. Both RILI and CIP share similar symptoms like fever, dry cough, and chest pain, and diagnosis involves symptom assessment and imaging such as computed tomography CT. This trial aims to find the best dose and evaluate the safety and effectiveness of pirfenidone capsules for treating RILI with or without CIP, addressing a critical need for better therapies. The study has two phases Phase II focuses on finding the optimal dose of pirfenidone, testing low-dose 400 mg three times daily, high-dose 600 mg three times daily, and placebo groups over 168 days of treatment and observation, followed by safety and survival follow-up. Phase III will confirm the chosen doses effects compared to placebo with a similar schedule and includes a long-term extension phase with survival assessments every three months. Participants will receive oral pirfenidone capsules or placebo with meals during the treatment period. Participants will undergo regular assessments including lung function tests like diffusing capacity of the lung for carbon monoxide DLCO, forced vital capacity FVC, and forced expiratory volume in one second FEV1. Other evaluations include symptom scores, CT imaging, blood tests, and monitoring for adverse events. The primary outcome is the change in lung diffusion capacity at 24 weeks. Safety follow-up occurs for about a month after treatment, and long-term monitoring continues in the extension phase. The total study participation spans from screening through treatment, safety follow-up, and extended survival tracking.

Researchers are evaluating the safety and effectiveness of TQC2731 injection in adults with severe asthma that is not well controlled. This is a Phase III clinical trial where 660 participants with asthma are randomly assigned to receive either TQC2731 or a placebo. The study aims to see if TQC2731 can reduce asthma worsening episodes over one year compared to placebo. Participants receive either the TQC2731 injection or placebo every four weeks for up to 48 weeks through subcutaneous injection. The treatment cycles repeat monthly from the start until Week 48. The study compares these two groups to assess the impact on asthma symptoms and lung function. Throughout the trial, participants will have regular assessments including lung function tests, asthma symptom diaries, quality of life questionnaires, and blood tests for inflammation markers and immune response. Researchers track the number of asthma exacerbations during the 52 weeks of treatment and up to 64 weeks for some outcomes. Safety and immune reactions are monitored carefully. The total study duration for each participant is about one year of treatment plus follow-up.